ReviewFrontiers in pharmacology2025
The therapeutic potential of icariin in the intervention of bone and joint diseases through multiple pathways: a narrative review.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Icariin-loaded liposomal nanoparticles alleviate streptozotocin-induced diabetic hepatopathy associated with modulation of ferroptosis-related and inflammatory signaling.BMC pharmacology & toxicology · 2026Article
- Classification, Structure-Activity Relationship, and Anti-Osteoarthritis Mechanism of Natural Flavonoids.Chemistry & biodiversity · 2026Review
- Review
- Targeting the osteoimmune microenvironment to prevent regulated chondrocyte death in osteoarthritis: therapeutic potential of natural products.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of bone and joint diseases is projected to increase owing to rapidly aging populations, sedentary lifestyles, and unhealthy diets. This poses a significant challenge for the global healthcare system. In recent years, natural herbal medicines have been used to treat various types of orthopedic diseases, opening new frontiers in new drug research. Epimedium is a traditional Chinese herb with a long history of medicinal use. It is commonly used to treat osteoporosis, joint disorders, cardiovascular diseases, sexual dysfunction and aging. The primary active component of Epimedium is icariin (ICA), an isoprenylated flavonoid. Recent studies have demonstrated its significant positive effects on bone metabolism and remodeling, including promoting osteoblast proliferation and mineralization, reducing osteoclast activity, and inhibiting inflammation and oxidative stress. Thus, ICA represents a potential compound for treating bone and joint diseases. However, the specific mechanisms underlying these effects have not yet been fully elucidated. This paper focuses on the latest advances in the use of ICA for the treatment of skeletal and joint diseases, covering a range of conditions including osteoporosis, osteoarthritis, rheumatoid arthritis, intervertebral disc degeneration and fractures. Building on this, we have systematically integrated its multi-target pharmacological mechanism network for the first time, elucidating its multi-pathway synergistic effects mediated by regulating the balance of the bone microenvironment. In summary, as a multi-target natural compound, ICA demonstrates significant translational medicine potential in the comprehensive treatment of bone and joint diseases, providing a critical theoretical foundation for the development of novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.